Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2025-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving specific first line treatments for Stage 3 or metastatic non-small cell lung cancer. Part 2 compares the efficacy of inupadenant to placebo when both are combined with carboplatin and pemetrexed for patients that progressed after receiving the same first line treatments for Stage 3 or metastatic non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: iTeos Belgium SA
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology that has relapsed or progressed

2. Measurable disease as defined by RECIST v1.1 criteria

3. PD-L1 expression status available at or after the time of diagnosis of advanced or metastatic NSCLC disease

4. Can provide existing biopsy taken within 2 years prior to entering trial or provide fresh biopsy

5. Have relapsed or progressed after prior anti- PD-(L)1 therapy as follows:

1. At least 12 weeks of treatment with only 1 line of anti-PD-(L)1 therapy (mono or combo) in the metastatic setting, without concomitant chemotherapy OR

2. At least 12 weeks of single-agent durvalumab

6. Adequate organ function

7. ECOG performance status of 0 to 1.

Exclusion Criteria:

1. Symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease.

2. Presence of active second malignancy

3. EGFR or ALK mutation. Participants with presence of other driver mutations are allowed if targeted therapy is not available as per local standard of care.

4. Preexisting gastrointestinal disorders/conditions that may interfere with ingestion or absorption of oral medications.

5. History of or active (non-infectious) pneumonitis/ interstitial disease or lung fibrosis, except for Grade 1 pneumonitis from prior chemoradiation therapy (Stage III patients).

6. History of or active autoimmune disease requiring systemic treatment in the last 6 months or persistent immune-mediated toxicity caused by checkpoint inhibitor therapy > Grade 2

7. Known active or chronic hepatitis B or C infection unless adequately treated for at least 4 weeks with no detectable viral load; known infection with human immunodeficiency virus (HIV) unless receiving antiretroviral therapy with well-controlled disease.

8. History of life-threatening toxicity related to prior immune therapy or any toxicity resulting in permanent discontinuation from prior therapy.

9. Diagnosis of immunodeficiency or any condition requiring concurrent use of systemic immunosuppressants or corticosteroids.

10. Active infection requiring systemic therapy ≤ 7 days prior to first dose of study treatment.

11. Any other oncologic treatments administered ≤14 days (<28 days in case of checkpoint inhibitor therapy) prior to first dose of study treatment. Also, ongoing adverse effects from such treatment > Grade 1 with the exception for alopecia and Grade 2 peripheral neuropathy.

12. Non-study related minor surgical procedure ≤7 days, or major surgical procedure of ≤ 5 weeks prior to first dose of study treatment.

13. Uncontrolled or significant cardiovascular disease

14. History of allergy or hypersensitivity to any of the study treatments.

15. Treatment with a live or live attenuated vaccine.

16. Treatment with moderate or strong inducers or inhibitor of CYP 3A4, inhibitors of P-glycoprotein, or substrates of breast cancer resistance protein

17. Pregnant or breast-feeding

18. Male and Female participants: Lack of agreement to use highly effective method of contraception during treatment and for 6 months after the last administration of chemotherapy